Trial Profile
Multicenter, Open-label Study to Assess the Pharmacokinetics (PK), Pharmacodynamics (PD), Efficacy, Safety, Tolerability, and Immunogenicity of a Single, Subcutaneous Dose of 100µg/kg XM22 in 21 Children With Ewing Family of Tumors or Rhabdomyosarcoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Aug 2017
Price :
$35
*
At a glance
- Drugs Lipegfilgrastim (Primary)
- Indications Ewing's sarcoma; Rhabdomyosarcoma
- Focus Pharmacokinetics
- Sponsors Merckle
- 17 Apr 2015 New trial record